Josh Lehrer, M.D., appointed as independent director at Fulcrum Therapeutics, brings extensive drug development experience to the board.
Quiver AI Summary
Fulcrum Therapeutics, Inc. has appointed Dr. Josh Lehrer to its Board of Directors as an independent director. Dr. Lehrer is a physician-scientist with extensive experience in clinical development and has served in various leadership roles in biotechnology companies, including his recent position as CEO of Marea Therapeutics and previously at Graphite Bio and Global Blood Therapeutics. His expertise in rare disease drug development, particularly in sickle cell disease, is expected to be valuable for Fulcrum as it advances its lead program, pociredir, a small molecule aimed at increasing fetal hemoglobin production for sickle cell treatment. Dr. Lehrer holds degrees from Harvard, the University of Cambridge, and UCSF, and he expressed enthusiasm for contributing to Fulcrum's mission of developing transformative therapies.
Potential Positives
- Dr. Josh Lehrer, a physician-scientist with over two decades of experience in clinical development, has been appointed to Fulcrum's Board of Directors, enhancing the company's leadership with his expertise in rare disease drug development.
- Dr. Lehrer has a proven track record, including his role in the development and approval of Oxbryta® for sickle cell disease, which aligns with Fulcrum's focus on advancing therapies for hematological disorders.
- His appointment is seen as a strategic advantage as Fulcrum continues to advance its lead clinical program, pociredir, which aims to address significant unmet medical needs in sickle cell disease.
Potential Negatives
- The press release highlights that the company is still in a clinical stage, indicating potential delays or uncertainties in the commercialization of their lead drug, pociredir.
- The mention of recent leadership changes may raise concerns regarding stability and continuity in the company's strategic direction.
- Dr. Lehrer's previous role as CEO of Graphite Bio ended less than a year ago, which may lead to questions about his recent performance and the reasons for his departure from that position.
FAQ
Who is Josh Lehrer, M.D.?
Josh Lehrer, M.D., is a physician-scientist and biotechnology executive with extensive experience in clinical drug development.
What role did Josh Lehrer take at Fulcrum Therapeutics?
He has been appointed as an independent director on Fulcrum Therapeutics' Board of Directors.
What is pociredir?
Pociredir is a small molecule being developed by Fulcrum for the treatment of sickle cell disease.
What is Fulcrum Therapeutics focused on?
Fulcrum Therapeutics focuses on developing small molecules that improve the lives of patients with rare hematological disorders.
What is the significance of Dr. Lehrer's appointment?
Dr. Lehrer's expertise in rare disease drug development is crucial for advancing Fulcrum's therapeutic pipeline, including pociredir.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FULC Insider Trading Activity
$FULC insiders have traded $FULC stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $FULC stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 0 purchases and 3 sales selling 4,175,139 shares for an estimated $58,377,021.
- ROBERT J GOULD has made 0 purchases and 2 sales selling 30,000 shares for an estimated $326,352.
- CURTIS GALE OLTMANS (Chief Legal Officer) sold 3,452 shares for an estimated $44,599
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$FULC Hedge Fund Activity
We have seen 102 institutional investors add shares of $FULC stock to their portfolio, and 62 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 4,175,139 shares (-40.8%) from their portfolio in Q4 2025, for an estimated $47,220,822
- BRAIDWELL LP added 2,841,734 shares (+1294.7%) to their portfolio in Q4 2025, for an estimated $32,140,011
- POINT72 ASSET MANAGEMENT, L.P. added 2,398,232 shares (+inf%) to their portfolio in Q4 2025, for an estimated $27,124,003
- SIREN, L.L.C. added 1,950,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $22,054,500
- FIRST TURN MANAGEMENT, LLC added 1,892,683 shares (+inf%) to their portfolio in Q4 2025, for an estimated $21,406,244
- ASSENAGON ASSET MANAGEMENT S.A. added 1,193,873 shares (+inf%) to their portfolio in Q1 2026, for an estimated $9,157,005
- SUVRETTA CAPITAL MANAGEMENT, LLC added 1,180,111 shares (+21.9%) to their portfolio in Q4 2025, for an estimated $13,347,055
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$FULC Analyst Ratings
Wall Street analysts have issued reports on $FULC in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/24/2025
- Truist Securities issued a "Buy" rating on 11/24/2025
- Piper Sandler issued a "Overweight" rating on 10/30/2025
To track analyst ratings and price targets for $FULC, check out Quiver Quantitative's $FULC forecast page.
$FULC Price Targets
Multiple analysts have issued price targets for $FULC recently. We have seen 7 analysts offer price targets for $FULC in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- An analyst from JP Morgan set a target price of $20.0 on 01/12/2026
- Gregory Renza from Truist Securities set a target price of $18.0 on 12/11/2025
- Tazeen Ahmad from B of A Securities set a target price of $7.0 on 12/09/2025
- Edward Tenthoff from Piper Sandler set a target price of $23.0 on 12/08/2025
- Andrew S. Fein from HC Wainwright & Co. set a target price of $25.0 on 12/08/2025
- Luca Issi from RBC Capital set a target price of $10.0 on 12/08/2025
- Kristen Kluska from Cantor Fitzgerald set a target price of $24.0 on 12/08/2025
Full Release
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hematological disorders, today announced that Josh Lehrer, M.D., M.Phil., FACC, has been appointed to its Board of Directors as an independent director.
Dr. Lehrer is a physician-scientist and biotechnology executive with more than two decades of clinical development experience across all stages of drug development. He currently serves as Chief Executive Officer and a member of the board of directors of Marea Therapeutics, a clinical-stage biotechnology company. Previously, Dr. Lehrer served as President and Chief Executive Officer of Graphite Bio, Inc. from April 2020 until September 2023. Prior to that, he was the Chief Medical Officer at Global Blood Therapeutics where he oversaw the development and approval of Oxbryta ® (voxelotor) for the treatment of sickle cell disease. Earlier in his career, Dr. Lehrer held clinical development and business development roles at Genentech.
“We are delighted to welcome Josh to Fulcrum’s Board of Directors,” said Alex C. Sapir, President and Chief Executive Officer of Fulcrum Therapeutics. “Josh brings deep expertise in rare disease drug development and a strong track record advancing transformative therapies, including his leadership in the development and approval of Oxbryta for patients with sickle cell disease. His experience will be invaluable as we continue advancing pociredir and our broader benign hematology pipeline.”
“I spent more than a decade working to develop new therapies for patients with sickle cell disease, and the need for effective, orally available treatments remains significant,” said Dr. Lehrer. “Fulcrum is advancing a promising approach with pociredir, supported by results from the PIONEER trial, and I look forward to working alongside the board and management team to help bring this therapy forward for patients.”
Dr. Lehrer received an A.B. in Biochemical Sciences from Harvard University and a Master of Philosophy in Biological Sciences from the University of Cambridge. He earned his Doctor of Medicine from the University of California, San Francisco and completed his residency in internal medicine at UCSF, followed by postdoctoral fellowship in cardiovascular medicine at Stanford University.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of people with rare hematological disorders. The company’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. For more information, visit
www.fulcrumtx.com
and follow us on X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
[email protected]
617-283-2856
